Drug Interaction Report

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 2C8 may significantly increase the plasma concentrations of resmetirom, which is primarily metabolized by the isoenzyme. When clopidogrel, a moderate CYP450 2C8 inhibitor, was administered concomitantly with multiple doses of resmetirom (100 mg daily) to study subjects, resmetirom peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.3-fold and 1.7-fold, respectively. The risk of adverse effects such hepatotoxicity, gallbladder-related adverse reactions, diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain, and dizziness may be increased. Clinical data exploring the use of potent CYP450 2C8 inhibitors (e.g. gemfibrozil) are not available.

MANAGEMENT: Concomitant use of resmetirom with potent CYP450 2C8 inhibitors should generally be avoided.